A man walks past the logo of Swiss drugmaker Novartis AG in front of a plant in Basel in this October 25, 2011 file photo. India’s highest court will hear final arguments starting this week in a landmark case over drug patents that could change the rules for the country’s healthcare sector and potentially curb its global role as a supplier of cut-price generic medicines, according to news reports on August 20, 2012. The Supreme Court hearing pits Swiss drugmaker Novartis AG against India’s patent office, which has refused to grant a patent on the company’s cancer drug Glivec on the grounds that it is not a new medicine but an amended version of a known compound. REUTERS/Arnd Wiegmann/Files (SWITZERLAND – Tags: BUSINESS HEALTH)